Lucjan Stanislaw Wyrwicz
The Maria Sklodowska-Curie National Research Institute of Oncology · 305 works · 15,351 citations · h-index 52
Top works
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- The Phaeodactylum genome reveals the evolutionary history of diatom genomes
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
- LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
- mRNA Cap-1 Methyltransferase in the SARS Genome
- Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
- LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
- Corrections to “Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
- Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
- Comprehensive classification of nucleotidyltransferase fold proteins: identification of novel families and their representatives in human
- Plant nitric oxide synthase: a never-ending story?
- Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
- Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
- Molecular phylogenetics of the RrmJ/fibrillarin superfamily of ribose 2′-O-methyltransferases
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
- SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies